Kate Burbury DPhil

Kate completed her training at RoyalHobartHospital in Tasmania, John Radcliffe in Oxford (inc DPhil at OxfordUniversity) and PeterMac; and has an active research program with a particular interest in the haemostatic/endothelial dysfunction associated with malignancy.

Kate has been actively involved in numerous clinical trials and is currently the lead PI for trials in malignant haematology, in particular chronic myeloid leukaemia and other myeloproliferative disorders. Other focus areas are thrombogenic biomarker profiles and thromboprophylaxis in all cancer patients